741 related articles for article (PubMed ID: 27865626)
1. Synergistic combinations of polymyxins.
Lenhard JR; Nation RL; Tsuji BT
Int J Antimicrob Agents; 2016 Dec; 48(6):607-613. PubMed ID: 27865626
[TBL] [Abstract][Full Text] [Related]
2. Resistance to polymyxins in Gram-negative organisms.
Jeannot K; Bolard A; Plésiat P
Int J Antimicrob Agents; 2017 May; 49(5):526-535. PubMed ID: 28163137
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.
Karakonstantis S; Kritsotakis EI; Gikas A
Infection; 2020 Dec; 48(6):835-851. PubMed ID: 32875545
[TBL] [Abstract][Full Text] [Related]
4. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T
Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770
[TBL] [Abstract][Full Text] [Related]
5. Polymyxins: Antimicrobial susceptibility concerns and therapeutic options.
Balaji V; Jeremiah SS; Baliga PR
Indian J Med Microbiol; 2011; 29(3):230-42. PubMed ID: 21860102
[TBL] [Abstract][Full Text] [Related]
6. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates.
Vidaillac C; Benichou L; Duval RE
Antimicrob Agents Chemother; 2012 Sep; 56(9):4856-61. PubMed ID: 22751540
[TBL] [Abstract][Full Text] [Related]
7. Performances of the Rapid Polymyxin
Lescat M; Poirel L; Jayol A; Nordmann P
Microb Drug Resist; 2019 May; 25(4):520-523. PubMed ID: 30508392
[No Abstract] [Full Text] [Related]
8. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.
Doymaz MZ; Karaaslan E
Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061
[No Abstract] [Full Text] [Related]
9. Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes.
Almangour TA; Garcia E; Zhou Q; Forrest A; Kaye KS; Li J; Velkov T; Rao GG
Int J Antimicrob Agents; 2021 Jun; 57(6):106328. PubMed ID: 33785362
[TBL] [Abstract][Full Text] [Related]
10. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
[TBL] [Abstract][Full Text] [Related]
11. Multidrug-Resistant Gram-Negative Pathogens: The Urgent Need for 'Old' Polymyxins.
Paterson DL; Bonomo RA
Adv Exp Med Biol; 2019; 1145():9-13. PubMed ID: 31364068
[TBL] [Abstract][Full Text] [Related]
12. The polymyxin derivative NAB739 is synergistic with several antibiotics against polymyxin-resistant strains of Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii.
Tyrrell JM; Aboklaish AF; Walsh TR; Vaara T; Vaara M
Peptides; 2019 Feb; 112():149-153. PubMed ID: 30586602
[TBL] [Abstract][Full Text] [Related]
13. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?
Falagas ME; Bliziotis IA
Int J Antimicrob Agents; 2007 Jun; 29(6):630-6. PubMed ID: 17306965
[TBL] [Abstract][Full Text] [Related]
14. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili A; Izanloo A; Rastegar M
Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
[TBL] [Abstract][Full Text] [Related]
15. Reviving Polymyxins: Achievements, Lessons and the Road Ahead.
Li J
Adv Exp Med Biol; 2019; 1145():1-8. PubMed ID: 31364067
[TBL] [Abstract][Full Text] [Related]
16. Rediscovering the octapeptins.
Velkov T; Roberts KD; Li J
Nat Prod Rep; 2017 Mar; 34(3):295-309. PubMed ID: 28180225
[TBL] [Abstract][Full Text] [Related]
17. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
Zhang X; Guo F; Shao H; Zheng X
J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
[TBL] [Abstract][Full Text] [Related]
18. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D
Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
[TBL] [Abstract][Full Text] [Related]
19. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis.
Ni W; Shao X; Di X; Cui J; Wang R; Liu Y
Int J Antimicrob Agents; 2015 Jan; 45(1):8-18. PubMed ID: 25465524
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
